These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) will likely be announcing its earnings results before the market opens on ...
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) was upgraded by Raymond James from an “outperform” rating to a “strong-buy ...
New Haven, Connecticut Tuesday, March 11, 2025, 18:00 Hrs [IST] ...
Trevi Therapeutics, Inc.’s TRVI share price has surged by 41.16%, which has investors questioning if this is right time to sell.
Trevi Therapeutics (Nasdaq: TRVI) reported promising results from a mid-stage study of its experimental chronic cough ...
Under the terms of the agreement, Redfin shareholders will receive 0.7926 shares of Rocket Class A common stock for each Redfin share—a 63% premium over Redfin’s 30-day volume-weighted average price.
Fintel on MSN4d
Raymond James Upgrades Trevi Therapeutics (TRVI)Fintel reports that on March 10, 2025, Raymond James upgraded their outlook for Trevi Therapeutics (NasdaqGM:TRVI) from ...
Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) ...
Trevi's Haduvio reduces chronic cough by 57% vs placebo in Phase 2a trial, surpassing expectations. Stock rises 40%.
The New Haven, Conn., biopharmaceutical company shared positive topline results from a Phase 2a trial of Haduvio for the treatment of patients with refractory chronic cough. Haduvio met the primary ...
Trevi Therapeutics (TRVI) surges 40% premarket as Haduvio proves effective in reducing chronic coughing in trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback